BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 5, 2004
View Archived Issues
Inhibitex Files For IPO; Veronate Slated To Start Phase III In 2004
Inhibitex Inc. joined the ranks of private biotech companies looking to take advantage of a more receptive market with an initial public offering filing aimed at raising $86.25 million. (BioWorld Today)
Read More
CTI Cleared For Pixantrone Trial; Strong Pipeline Backs NHL Drug
Read More
Legislation Could Help Patent Office Keep Fees, Add To Staff
Read More
After Pulling IPO, Acorda Raises $11.5M Through Private Round
Read More
Other News To Note
Read More
U.S. Patent Disclosures
Read More